TENX
SHORT CANDIDATEMeanRevComposite
20.60
Technical
5.30
Fundamental
25.70
Rank
—
Price
1.76
Hurst
0.29
As of
Oct 23, 2026
Daily
Tenax Therapeutics, Inc.
HealthcareBiotechnologyTenax Therapeutics is a pharmaceutical development company focused on cardiopulmonary treatments. The company is advancing multiple drug candidates including TNX-101, TNX-102, and TNX-103 (levosimendan) for pulmonary hypertension associated with heart failure, along with TNX-201 (imatinib), a tyrosine kinase inhibitor being developed for chronic myeloid leukemia. Headquartered in Chapel Hill, North Carolina, the company was established in 1967 and operates primarily in the United States.
Market cap
$67.0M
P/E (trailing)
—
P/E (forward)
-1.19
PEG ratio
1.44
Dividend yield
0.00%
Beta
0.92
52w range
1.31 – 19.40
Return on equity
-59.80%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 1.79 (-75.6%) · range 1.36–18.32
Cycle position
24/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 55 · MODERATE · exit proximity 0
Conviction
37/ 100 · maturity 29%
VScore.1614
Buildup.2834
EMA entry setup.3555
Fundamentals.2126
Volume profile
POC
1.85
Price vs POC
-3.4%
Overhead supply
61%
Runway
+3.5%
Value area 1.31–2.03 · 61% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| insider-activity | 0.400 | Oct 23, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +0.54% | +6.45% | mature |
| 40d | -7.53% | +6.45% | 30/40d |